Charles Baroud - Physical Microfluidics and Bioengineering
In this group, the scientists are using microfluidic tools and imaging to study the emergence of antibiotic resistance at the scale of individual cells.
Frederic Barras - Stress adaptation and metabolism in enterobacteria
Understanding molecular, metabolic and physiological mechanisms of antibiotic activity and of phenotypic resistance.
Gregory Batt - InBio: Experimental and Computational Methods for Modeling Cellular Processes
This unit is developing models to characterize individual and collective antibiotic resistance to -lactams, together with algorithms and experimental platforms for their automated and efficient calibrations.
Christophe Beloin - Genetics of Biofilms
This unit aims at understanding the molecular mechanisms beyond the extreme tolerance of biofilms towards antibiotics and the link between this tolerance and evolution of resistance in order to identify novel strategies to fight biofilm-associated infections and to reduce emergence of antibiotic resistance.
David Bikard - Synthetic Biology
The Synthetic Biology group is developing CRISPR tools to study and fight antibiotic resistant bacteria.
Sylvain Brisse - Biodiversity and Epidemiology of Bacterial Pathogens
The scientists use genomics and bioinformatics to understand the global dissemination of multidrug resistance strains and they provide to the community, unified nomenclatures (“genomic taxonomies of strains”) that allow global communication on strain subtypes and their tracking across time, geography and activity sectors (“One Health”).
Carmen Buchrieser - Biology of Intracellular Bacteria
This unit is investigating how immunological responses, metabolic signalling, metabolic fluxes, and subcellular architecture of host cells are modified during infection by intracellular pathogens using Legionella pneumophila as a model. This knowledge will be used to identify immunometabolic drugs to tackle infection and to target host pathways instead of the pathogen.
Nienke Buddelmeijer - Biology and Genetics of Bacterial Cell Wall
Lipoprotein modification in bacteria: a novel target for antibiotics
Dominique Clermont - Biological Resources Center
Screening for metabolites potentially usable as new antimicrobials and Study of the history and evolution of resistance in ESKAP pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa) are expanding the bacterial landscape of innovative solutions to combating AMR today.
Laurent Debarbieux - Molecular Biology of Gene in Extremophiles
Using animals models, this group is elucidating the mechanisms supporting the efficacy of bacteriophages for treating infections caused by AMR bacteria.
Caroline Demangel - Immunobiology of Infection
This unit aims to determine whether host-derived lipids may function as natural antibiotics, and can be considered as effectors of the innate immune system.
Hilde De-Reuse - Helicobacter Pathogenesis
Understanding the mode of action of existing medications and investigating new targets and molecules to fight infection by Helicobacter pylori, a priority pathogen for AMR that is responsible for 800,000 deaths every year worldwide.
Guillaume Dumenil - Pathogenesis of vascular infections
An anti-virulence strategy based on the inhibition of type IV pili is efficient on various bacteria including antibiotic resistant Neisseria gonorrhoeae.
Bruno Dupuy - Pathogenesis of Bacterial Anaerobes
Development of new therapeutic potentials against Clostridium difficile.
Olivier Dussurget - Yersinia
Design and synthesis of NAD kinase inhibitors as novel antibacterial agents.
Jost Enninga - Dynamics of Host-Pathogen Interactions
Using an interdisciplinary research approach, this unit investigates how bacterial pathogens subvert host cells to reach intracellular niches to escape from antimicrobials and the host immune response.
Jean-Marc Ghigo - Genetics of Biofilms
Identification of functions promoting the rise and fall of antibiotic-tolerant bacterial biofilms.
Philippe Glaser - Ecology and Evolution of Antibiotics Resistance
This unit is addressing a major threat in antibiotic resistance: the global dissemination of multidrug resistant (MDR) lineages and of antibiotic resistant genes. The scientists are focusing on carbapenemase producing enterobacteriaceae which are considered by WHO as “critical” priority pathogens.
Ivo Gomperts-Boneca - Biology and Genetics of Bacterial Cell Wall
Searching for new therapeutic strategies targeting the assembly of the cell wall of bacteria.
Simonetta Gribaldo - Evolutionary Biology of the Microbial Cell
By studying fundamental cellular processes in bacteria and archaea, the researchers can discover novel targets for antimicrobial agents.
Didier Guillemot - Biostatistics, Biomathematics, Pharmacoepidemiology and Infectious Diseases
This team aims at decipheing dynamic causal links between human contacts, bacterial intrinsic transmission capacities for resistant gene vectorization, factors affecting human and environmental microbiota disruption, and the burden of antibiotic resistance.
Melanie Hamon - Chromatin and Infection
The work of this unit focuses on bacteria-host interactions, with the aim to target host mechanisms essential for bacterial growth and find alternatives to current direct-acting anti-bacterial drugs.
Molly Ingersoll - Mucosal Inflammation and Immunology
This group is developing non-antibiotic based immunomodulatory therapeutic approaches to combat multidrug resistant urinary tract infections.
Daniel Ladant - Biochemistry of Macromolecular Interactions
The goal of this unit is to exploit an innovative and robust target-based in vivo screening pipeline based on a robust bacterial two hybrid screening technology (BACTH) to identify small-molecules able to block the assembly of bacterial cell division machinery.
Marc Lecuit - Biology of Infection
The researchers follow an interdisciplinary approach to understand Listeria biology, its pathogenic potential and saprophytic life, and its dynamics within and outside the host.
Emmanuel Lemichez - Bacterial Toxins
This team pursues novel promising approaches aiming at fighting toxi-infections through development of chemical compounds acting directly on host components to confer to cells resistance properties to the arsenal of pathogens and stimulate innate immune responses.
Giulia Manina - Microbial Individuality and Infection
Drug enhancers that target phenotypic variation to accelerate treatment and prevent resistance.
Didier Mazel - Bacterial Genome Plasticity
This team fights resistance from both side: understanding the genetics behind its development and proposing alternate antimicrobial strategies.
Javier Pizarro-Cerda - Yersinia
This unit investigates both novel compounds against essential bacterial genes as well as novel bactericidal molecules against Gram-positive pathogens.
Eduardo Rocha - Evolutionary Microbial Genomics
This lab uses bioinformatics, genomics, metagenomics, and experimental approaches to understand how mobile genetic elements drive bacterial adaptation by way of horizontal gene transfer, including the acquisition of antibiotic resistance genes.
Brice Sperandio - Molecular Microbial Pathogenesis
Deciphering the regulation of human innate antimicrobial mechanisms to develop innovative immuno-stimulatory molecules.
Lhousseine Touqui - Group: Cystic Fibrosis and Bronchial Diseases
The use of antimicrobial peptides (AMPs) combined with nanoparticles (NPs) to fight multi-resistant bacteria.
Sven Van-Teeffelen - Microbial Morphogenesis and Growth
This lab works on the ability of cells to protect their mechanical integrity against cell-wall damage caused by antibiotics and other stresses, largely using single-cell time-lapse microscopy.
Francois-Xavier Weill - Enteric Bacterial Pathogens
Thanks to a unique of historical bacterial isolates and collaboration with clinical laboratories, food and veterinary agencies at national or international level, these scientists can carry out large-scale genomic studies, to determine population structures, phylogeographic patterns, and genetic evolution of antibiotic resistant enteric bacterial populations.